Xeris Biopharma Holdings, Inc.
XERS
$4.16
$0.215.32%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 61.81% | -29.12% | 24.38% | -12.75% | -3.56% |
| Total Depreciation and Amortization | -3.87% | -6.94% | -6.21% | 1.04% | -6.97% |
| Total Amortization of Deferred Charges | 56.36% | 40.63% | 44.36% | 4.56% | 17.63% |
| Total Other Non-Cash Items | 926.83% | -40.15% | 291.84% | -36.45% | 89.45% |
| Change in Net Operating Assets | -102.71% | 106.08% | -398.68% | 59.35% | 682.15% |
| Cash from Operations | -73.56% | 43.16% | 24.71% | 22.33% | 146.35% |
| Capital Expenditure | -66.67% | 74.78% | 74.35% | 31.09% | 0.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -31.76% | -33.33% | -50.00% | 55.45% | 61.29% |
| Cash from Investing | -32.63% | -32.35% | -45.54% | 55.32% | 62.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 22.20% | -- | -100.00% |
| Repurchase of Common Stock | -238.78% | -15.28% | -104.00% | -297.91% | -133.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -1,875.00% |
| Cash from Financing | 132.25% | -15.28% | 18.53% | 4,178.10% | -102.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -41.30% | 5,751.85% | -7.39% | 93.30% | -49.99% |
